Clinical Trials
33 trialsNCT03933826 2026-05-12
CISTO
University of Washington
Active not recruiting
NCT05243550 2026-05-11
ENVISION
UroGen Pharma Ltd.
Phase 3 Active not recruiting
NCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT04165317 2026-01-22
CREST
Pfizer
Phase 3 Active not recruiting
NCT04897763 2026-01-07
PERTINENCE
Institut Cancerologie de l'Ouest
Phase EARLY_PHASE1 Completed
NCT04386746 2025-11-17
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT03081858 2025-06-27
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
Phase 1/2 Completed
NCT04690699 2024-10-24
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
Istari Oncology, Inc.
Phase 1/2 Terminated
NCT05136898 2024-09-19
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 3 Completed
NCT02773849 2024-07-29
ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Ferring Pharmaceuticals
Phase 3 Completed
NCT01625260 2024-07-19
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience
Phase 1/2 Terminated
NCT04688931 2024-06-06
ATLAS
UroGen Pharma Ltd.
Phase 3 Terminated
NCT03636256 2023-08-14
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
NanOlogy, LLC
Phase 1/2 Completed
NCT02449239 2023-07-24
VISTA
Sesen Bio, Inc.
Phase 3 Completed
NCT03519256 2023-06-01
CheckMate 9UT
Bristol-Myers Squibb
Phase 2 Terminated
NCT02695771 2023-04-21
BIC
Corewell Health West
Phase 3 Completed
NCT03558503 2022-09-16
OPTIMA II
UroGen Pharma Ltd.
Phase 2 Completed
NCT02316171 2022-07-27
CANON
Viralytics
Phase 1 Completed
NCT00318643 2021-10-29
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
Halozyme Therapeutics
Phase 1/2 Completed
NCT02563561 2021-10-27
A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT02009332 2021-06-08
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Aadi Bioscience, Inc.
Phase 1/2 Completed
NCT03498196 2020-08-24
A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer
Baylor College of Medicine
Phase 1/2 Terminated
NCT03719300 2020-08-19
Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC
Anchiano Therapeutics Israel Ltd.
Phase 2 Terminated
NCT03167151 2020-07-31
PemBla
University of Oxford
Phase 1/2 Terminated
NCT00595088 2019-04-30
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Anchiano Therapeutics Israel Ltd.
Phase 2 Completed
NCT02605863 2018-10-03
Enzalutamide for Bladder Cancer Chemoprevention
University of Rochester
Phase 2 Terminated
NCT02560584 2018-07-02
A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Photocure
Phase 3 Completed
NCT01469221 2017-12-15
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01687244 2017-07-24
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
FKD Therapies Oy
Phase 2 Completed
NCT01410565 2016-12-13
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT00734994 2015-06-29
Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
Duke University
Phase EARLY_PHASE1 Completed
NCT02207608 2015-05-28
Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects
University of Rome Tor Vergata
Phase 2 Completed